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In 1927 Otto Warburg established that tumours derive energy primarily from the conversion of glucose to lactic acid and only
partially through cellular respiration involving oxygen. In the 1950s he proposed that all causes of cancer reflected different
mechanisms of disabling cellular respiration in favour of fermentation (now termed aerobic glycolysis). The role of aberrant
glucose metabolism in cancer is now firmly established. The shift away from oxidative phosphorylation towards the metabol-
ically expensive aerobic glycolysis is somewhat counter-intuitive given its wasteful nature. Multiple control processes are in
place to maintain cellular efficiency and it is likely that these mechanisms are disrupted to facilitate the shift to the reliance
on aerobic glycolysis. One such process of cell control is mediated by the nuclear receptor superfamily. This large family of
transcription factors plays a significant role in sensing environmental cues and controlling decisions on proliferation, differen-
tiation and cell death for example, to regulate glucose uptake and metabolism and to modulate the actions of oncogenes and
tumour suppressors. In this review we highlight mechanisms by which nuclear receptors actions are altered during tumori-
genic transformation and can serve to enhance the shift to aerobic glycolysis. At the simplest level, a basic alteration in NR
behaviour can serve to enhance glycolytic flux thus providing a basis for enhanced survival within the tumour micro-
environment. Ameliorating the enhanced NR activity in this context may help to sensitize cancer cells to Warburg targeted
therapies and may provide future drug targets.
Nuclear Receptors Respond to Environmental
Signals
The Nuclear receptor (NR) super-family of transcription fac-
tors have wide-ranging actions. NRs sense environmental,
systemic and local factors by binding a wide range of lipo-
philic molecules. They respond by regulating transcriptomes
inﬂuencing fundamental processes such as proliferation and
differentiation. Ligands for NRs are frequently derived from
dietary derived factors and metabolism, and regulate proc-
esses such as glycolysis, oxidative phosphorylation and fatty
acid synthesis (reviewed in Refs. 1–3). To achieve these
actions NR bind with a variety of co-activators, co-repressors
and histone modifying enzymes to form large DNA associ-
ated complexes that regulate chromatin structure and gene
transcription (reviewed in Ref. 4).
Functionally, the 48 members of the human NR super-
family fall into three main groups. Firstly, are those with
high-afﬁnity for ligand, such as steroidal receptors (e.g. AR
and ERa) and seco-steroidal receptors such as VDR and
the RARs. The VDR and RARs respond to dietary factors
including vitamin D3 and retinoids and do so at the low
nM range, although there is evidence for low afﬁnity bind-
ing to other dietary compounds, for example the VDR can
bind certain bile acids.5 The second group including the
PPARs, FXRs, and LXRs have low binding afﬁnities, but for
a wider range of lipophilic molecules. These NRs respond
to lM concentrations of dietary derived factors such as
fatty acids and glucose. The classical steroid NRs are pre-
dominately in the cytoplasm in the absence of ligand and
are shuttled in when activated. By contrast the VDR and
RARs, and many other NRs that bind ligand with low afﬁn-
ity are bound to chromatin in the absence and presence of
ligand; the addition of ligand re-distributes the receptor
and changes the gene regulation function, generally to acti-
vation. Thereby regulating gene expression in the presence
and absence of ligands allows distinct responses based on
the local microenvironment, cellular milieu or other
factors.
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The ﬁnal group, the orphan NR, are receptors for which
either ligands have not yet been identiﬁed or contain no
ligand binding domain, examples include NR4A1/NUR77
and ERRs. These orphan receptors frequently utilize co-
factors in place of a true ligand, so can be regulated as the
other two classes are but through changes in protein
bioavailability.6,7
It has emerged that this receptor superfamily is centrally
placed to regulate many pathways relating to energy metabo-
lism and that analyses of their function has been central to
the development of the ﬁeld of Molecular Endocrinology.8
These features pivotally position the NR superfamily to medi-
ate cellular response to changes in nutrient availability and
systemic and inter-cellular signaling. Coupled with these
functions, it is also clear that their activity is frequently
altered in cancer, and surprisingly, as a family, their expres-
sion is signiﬁcantly distorted more than predicted by chance.9
Together, therefore, by physiological and pathophysiological
function the NRs appear to be intimately placed within the
signaling cascades that are central to the Warburg effect.
The Central Cellular Role of ATP Production and the
Warburg Effect
A primer on ATP production
Given that ATP is the fundamental energy unit of the cell, its
generation is vital to maintain processes such as transporting
molecules against concentration gradients, and protein and
nucleic acid synthesis. Additionally the growing cell needs to
make a choice over whether to divert glucose away from
ATP production either to de novo fatty acid synthesis for the
generation of cellular structures, or aromatic amino acids to
aid in protein synthesis. The synthesis of ATP is therefore a
tightly controlled process within the cell and there are many
points during the generation of ATP on which signaling cas-
cades converge to bring about changes to ATP ﬂux. Glucose
metabolism provides the most efﬁcient method of generating
energy within the cell; other compounds such as proteins and
fatty acids may be utilized but give reduced efﬁciency in the
net generation of ATP. Glucose is therefore initially used as a
substrate for glycolysis, and its breakdown products are,
under normal aerobic conditions, also substrates for the citric
acid cycle and oxidative phosphorylation (OXPHOS). For
further information the reader is directed to some detailed
reviews.10–12
Given this role for glucose, there are a host of glucose
receptors present on the cell surface and the number and
type of transporter vary greatly depending on the tissue and
cell type and with disease status. Hexokinase is the ﬁrst of
several regulatory enzymes to process glucose and modiﬁes it
through phosphorylation to glucose-6-phosphate (G-6-P), the
substrate for the rest of glycolysis and the pentose phosphate
shunt (PPS). As G-6-P is not able to bind to glucose trans-
porters, and can be converted to storage molecules such as
glycogen, hexokinase has a key regulatory role by depleting
the local levels of free glucose in the cell. For every one mole-
cule of glucose, the immediate enzymatic reactions that ensue
result in a net increase of two molecules each of ATP and
pyruvate. Under normal aerobic conditions pyruvate is
imported the mitochondria and is metabolized to Acetyl-
CoA, a precursor of citrate, which is central to the citric acid
cycle and fatty acid synthesis. Under these conditions maxi-
mum chemical potential (about 36 ATPs) is extracted via the
metabolism of citrate into NADH and FADH2 and ﬁnally
ATP using the electron transport chain. Under anaerobic
conditions, however, such as heavy muscle use, pyruvate
entry to the mitochondria is prevented and is rapidly utilized
(3100 faster than under aerobic conditions during
OXPHOS) to generate a small amount of ATP (a net increase
of just two ATPs) via lactate dehydrogenase (LDH) metabo-
lism to lactic acid. This process is extremely inefﬁcient at
extracting chemical potential from the glucose; <5% of the
total possible ATP is formed.
The Warburg effect—A metabolic shift
Production of ATP via “fermentation” as described by Otto
Warburg, (now termed aerobic glycolysis) is a key feature of
many cancer cells.13 Tumor initiation and progression
requires selection for the most aggressive and resilient cells to
power and sustain proliferation and survival. Pathways such
as glycolysis, oxidative phosphorylation and fatty acid synthe-
sis are de-regulated to meet the requirements for ATP and
precursors for de novo biomass.14 Thus, the strong selection
pressures within the tumor micro-environment selects for
clones that can generate ATP rapidly at the expense of efﬁ-
ciency whilst also providing the necessary nutrients for rapid
cellular division.13,15,16 The observation that tumours produce
massive amounts of the aerobic glycolysis waste product, lac-
tic acid was central to the concept of deregulated metabo-
lism17,18 and that cancer was even termed “disorder of
metabolism.”19 Although cancer is now more accurately
deﬁned in terms of genomics, it remains clear that there are
substantial changes to metabolic pathways as result of genetic
and epigenetic changes. This hallmark of cancer, now known
as the Warburg effect, is so widespread and palpable that it
has been used to identify primary and metastatic lesions
through radio labeled glucose analogues combined with PET
scanning for the last 20 years.20
Speciﬁcally, the Warburg Effect describes what happens in
cancer cells when, although oxygen is plentiful, the cell shifts
in preference of generating ATP away from the efﬁcient oxi-
dative phosphorylation and towards the rapid aerobic glycol-
ysis. Although wasteful of glucose, this has signiﬁcant
beneﬁts for the tumour cell. Aerobic glycolysis produces ATP
far quicker than the slow route of oxidative phosphorylation
and results in the generation of crucial precursors for bio-
mass production such as NADPH which is not produced at
such levels via oxidative phosphorylation.16 It is hypothesized
that cancer cells utilize the rapid generation of ATP and the
increase in de novo fatty acid synthesis to grow and divide
quickly. The quickest dividing cells are by deﬁnition the ones
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to form the bulk of the tumor, in so long as their growth can
be sustained.
Selection for induction of the Warburg shift is therefore
likely, but whether this shift is a cause of cancer (due to the
accelerated mutation rate in uncontrollably dividing cells) or
a consequence downstream of other initiation events has not
been experimentally validated. Irrespective of the cellular ori-
gins of these adaptations, the advantages to the cell are
obvious; this shift not only allows rapid generation of ATP,
fatty acids and nucleotides whilst glucose is abundant, but
the generation of lactic acid ensures a tumour micro-
environment protective against immune attack.21 Further-
more, glucose ﬂux modeling has indicated that mere presence
of glucose elevated above a molecular tipping point turns the
cell to be energetically in favour of aerobic glycolysis over
oxidative phosphorylation, even in normal cells suggesting a
role for cytosolic glucose sensors.22 Glucose ﬂux and intracel-
lular concentrations in the cancer cell could therefor be the
trigger for the Warburg effect to occur.
NR Signaling Impacts on Glucose Metabolism
Increased glucose uptake in cancer
The ultimate gatekeepers for the glucose avarice of tumor
cells are the family of transport proteins that regulate the
import of glucose. There are three classes of SLC2A/GLUT
transport proteins and are grouped based on their sequence
homology.23 In normal biology several GLUTs are expressed
in insulin and insulin growth factor (IGF) sensitive tissues
and respond to the presence of both Insulin and the IGFs.24
The class I GLUTs (1–4) appear especially important in can-
cer progression.25 GLUT1 expression predicts survival in
bladder cancer patients26 and non-small cell lung tumour,27
presence of thyroid cancer28 and marks advanced breast can-
cer stages and breast cancer cells with high proliferative
potential.29 GLUT1 is also upregulated in colorectal cancers
displaying KRAS or BRAF mutations. Intriguingly, however,
this stems from glucose deprivation driving mutations in one
of the two oncogenes as a way of redressing the glucose lev-
els.30 When cells with wild-type KRAS were deprived of glu-
cose surviving cells showed a signiﬁcant mutation rate in the
KRAS allele and GLUT1 expression was elevated.
Reﬂecting the importance of GLUTs, their expression is
tightly controlled, for example by repression by wild-type but
not mutated p53.25 Class I GLUT expression and activity is
controlled by a range of NRs (Fig. 1). All class 1 GLUTs
show tissue speciﬁc expression to some extent and are fre-
quently over expressed in a range of tumour types. GLUT-4
expression, for example, is altered in breast cancer31,32 and is
translocated to the plasma membrane in an ER dependent
manner.33 PR as well can act alone and synergistically with
ER to elevate GLUT4 expression and increase glycolytic
ﬂux.34
The TR binds and regulates expression of GLUT1,
GLUT3, and GLUT4 in several cell types35–38 both directly
and indirectly through TR-mediated activation of PI3K and
stabilization of HIF1a and mTORC1.39 There is evidence
that constitutive over-production of the ligand T3 is caused
by a point mutation in the TSH gene40 and that this excess
T3 may over stimulate transcription of its downstream tar-
gets. Indeed, a range of cancer patients have signiﬁcantly ele-
vated levels of circulating T3, T4 and TSH and that the levels
of these factors correlated with development of carcinogene-
sis.41 Furthermore, Itoh et al. found that TRa1 mutant knock
in mice were less able to utilize glucose in the brain,42,43 but
this mechanism in cancer has not been assessed.
Under normal conditions, GLUT4 imports glucose in adi-
pocytes, in a T3 regulated manner.
44 PPARd regulates expres-
sion of TR directly and also combines with insulin signaling
to induce uptake and storage of glucose in adipose tissue.45
However, PPARd is unable to upregulate GLUT4 directly, as
demonstrated by the observation that GLUT246 but not
GLUT445 is induced in mice treated with the PPARd agonist
GW501516. GLUT4 is, however, directly regulated by PPARg
through a validated PPRE in its promoter; ingestion of the
PPARg agonist pioglitazone by obese Zucker rats led to sig-
niﬁcant increase in expression of this transporter.47 The VDR
is also able to upregulate GLUT1 and GLUT4 expression in
response to calcitriol in normal tissue, this upregulation was
signiﬁcantly more in diabetic models.48
Combinatorial NR gene regulation
Often multiple receptors bind at compound response ele-
ments. Most frequently there is kinetic competition for the
common heterodimer and transactivation partner RXR.
Other interactions include competitive binding; TRa can
Figure 1. The interface between nuclear receptor signaling the War-
burg effect. Multiple nuclear receptors (TR, ER, PR, PPARs, ERR,
LXR, CAR) regulate expression of glucose transporters (such as
GLUT4) and the downstream metabolic enzymes that handle its
metabolism. Interestingly glucose has been to shown to activate
LXR receptors directly.
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bind the PPRE at the AOX promoter and prevent access for
the PPARd/RXR heterodimer49 thus antagonizes PPAR
induced reporter gene expression.50 TRa also appears to be a
dominant regulator of PPARg genes at some loci.51 Another
type of interaction occurs at the CYP7A1 promoter where a
compound PPARa-LXRa response element exists. Stimula-
tion of either factor leads to gene expression, but stimulation
of both prevents expression as the PPAR-LXR dimer binds
instead of PPAR-RXR or LXR-RXR.52 This probably occurs
throughout the genome; LXR and PPAR bind several degen-
erate response elements in direct competition with each other
and with ChIP-Seq PPAR has been shown to bind to approx-
imately 75% of all LXR sites.53
Given that Class I GLUTs are frequently dependent upon
IGF signaling, the role for NR regulation in this process is
complex. Whilst there appears to be a linear path for activa-
tion of GLUT gene transcription by many NRs, they also sta-
bilize IGF activity through the induction IGF binding
proteins (IGFBPs).54–57 Conversely, the transcriptional co-
repressors NCOR1 and NCOR2/SMRT are frequently ele-
vated in different tumour types56,58–60 and prevents expres-
sion of many NR targets, including IGF1.61 However, these
co-repressors are themselves under transcriptional control of
multiple NRs including the ER62 and the VDR,63 allowing
tight feed-back regulation to balance the pro-proliferative and
anti-glycolytic function of NR co-repressors, as has been
described in breast cancer. These observations suggest that
tumours selectively target portions of the NR transcriptome
to repress or enhance depending upon suitability for advanc-
ing tumour growth.
Glucose retention by hexokinase II
Glucose is efﬁciently retained within the cancer cell through
enhanced heoxokinase activity. Hexokinase II (HKII) con-
verts glucose to G-6-P and is a rate-limiting step for of ATP
generation. HKII is particularly interesting as, in contrast to
the other HK isoenzymes, it is over expressed in many can-
cers; it has a very high afﬁnity for glucose, both catalytic
domains rather than just one are active and it is tethered to
the mitochondria allowing access to ATP and avoiding its
product-inhibitor G-6-P (reviewed in Ref. 64).
Several NR converge on the regulation of HKII expression
(Fig. 1), both directly through PPARg,65 CAR,66 ERR67,68 and
indirectly69,70 for example, through LXR activation of
SREBP1.71 NRs probably also contribute to its expression
through their effects on PI3K activity. Despite HKII respond-
ing directly to glucose through elevated gene expression,72 a
characterized glucose cis-element within its promoter has not
been identiﬁed. LXR is an intriguing candidate for this role.
It is a glucose responsive transcription factor73 and frequently
binds to PPAR compound elements53 (discussed above in
Combinatorial NR gene regulation section) of which several
have been identiﬁed in the HKII promoter. It will be of inter-
est to determine whether LXR shares a compound element
with the characterized PPAR response element in the HKII
promoter and whether LXR antagonists prevent glucose
mediated induction of HKII expression.
Enhancement of glucose metabolism
Free glucose (or G-6-P) can bind LXRs and induce transacti-
vation of LXR targets genes involved in cholesterol, fatty acid
and carbohydrate metabolism.73 LXRs are expressed widely
and in both normal and tumorigenic breast74 and prostate
cells.75,76 Considering the huge intake of glucose in cancer
cells, there is a signiﬁcant amount of substrate for the LXR
to interact with. However, as many NR are regulated by co-
repressors and co-activators,77 the mere presence of ligand
may not be sufﬁcient to induce gene expression.
The co-repressors NCOR1 and NCOR2/SMRT limit sig-
naling of NRs including LXRs, PPARs, VDR and RARs.56,58–
60,78–82 This distortion results in selective skewing of the tran-
scriptome (reviewed in Ref. 4). It remains a tantalizing possi-
bility that LXRa signaling is similarly distorted to sustain the
capacity of glucose to signal and facilitate further the War-
burg effect. Indeed there is evidence this may occur; LXR has
higher basal mRNA levels in prostate cancer cells than non-
malignant counterparts and have diminished sensitivity to
natural LXR ligands.60 This is in agreement with data from
the SAGE genie anatomical viewer which indicates LXRa
shows approximately sevenfold mRNA elevation in tumour
compared to non-malignant matched tissue. LXR agonism
has signiﬁcant anti-tumour function through inhibition of
Akt activity in a cholesterol-mediated manner,83 so whether
it acts with oncogenic or tumour suppressor behaviour is
unclear. Nonetheless epigenetic mechanism mediated via dis-
torted co-repressor interactions may be central to the selec-
tive distortion of LXRs actions.
Glucose also induces FXR mRNA and protein expression
and cooperates with FXR ligands to additively regulate sev-
eral FXR targets involved in triglyceride and bile acid homeo-
stasis.84 This is counter to the actions of insulin which
inhibit FXR expression and FXR mRNA is lowered in two
rat models of diabetes.84 Again, there is reasonable evidence
in malignancy that the normally well integrated actions of
FXR are selectively disrupted and an oncogenic subset of the
transcriptome is maintained in a transcriptionally responsive
manner.59,85–87
These examples highlight the fact that there are several
GLUT transporters controlled by NRs that are deregulated in
cancer, which lead to increased levels of substrate for the
metabolic pathways. A signiﬁcant association occurs between
expression of these GLUT family members and the selective
and enhanced functions of key NR such as TR and LXR. In
addition to enhancing transport of glucose, NRs can enhance
the rate at which conversion to G-6-P by HKII occurs. The
mere presence of excessive glucose within the cell appears
sufﬁcient for the cell to switch to aerobic glycolysis as a pref-
erential form of energy generation.22 NR deregulation may
therefore aid in the shift to aerobic glycolysis solely because
of elevated glycolytic ﬂux. This is an attractive hypothesis as
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it supports the idea that mitochondrial dysfunction is not
necessarily a pre-requisite for the Warburg shift.88
Downstream of the initial step of sequestration in glucose
metabolism comes the key conversion of pyruvate to lactic
acid. This reaction is controlled by the opposing actions of
the LDH-A (forward) and LDH-B (reverse) isoforms.89 Loss
of LDH-B is an early event in breast cancer through pro-
moter DNA methylation90 and LDH-A expression, which
drives conversion of pyruvate to lactate, is signiﬁcantly
enhanced in many cancer types. MYC and hypoxia91 increase
transcriptional expression of LDH-A. ChIP assays also
revealed that ERRa binds to response elements within the
promoters of both LDH-A and LDH-B isoforms in human
thyroid cancer tissue and induces LDH gene expression.92
The involvement of the nuclear co-activator, PGC-1a,
adds a layer of subtlety to the transcriptional relationship
between ERRa and LDH. In skeletal cells, under oxidative
stress induced by exercise, PGC-1a is able to differentially
regulate the two major LDH isoforms. Using ERRa as a
direct intermediaory, PGC-1a increases the ratio of LDH-B/
LDH-A.93 Direct stimulation of PPAR-b/d may also support
LDH-B expression in tumours as these NRs are able to
induce expression of LDH-B via AMPK and MEK2.94 LDH-
B may also be driven indirectly by PPAR-g through tran-
scriptional activation of MEF2. Conversely, Estradiol (E2)
induces expression of LDH-A in the rat via its control over
the CREB transcription factor.95 A contribution to the effects
of selective ER modulators (SERMs) is likely to be antagoniz-
ing lactate production.
Enhanced glucose metabolism influences the tumor
microenvironment
A major corollary of enhanced glucose metabolism is the
inﬂuence of the epithelial tumour cells over its microenviron-
ment. The excretion of lactic acid causes acidiﬁcation of the
local area. The roles of Carbonic anhydrase XII (CA12) and
monocarboxylate transporters (MCT) in this process of acidi-
ﬁcation are increasingly apparent. CA12 catalyzes conversion
of CO2 to bicarbonate thus acidifying the local region. MCTs
are major transporters of lactate and other proton donating
moieties. In breast cancer CA12 expression is tightly linked
to ERa levels and estradiol stimulates its expression. Using
chromatin conformation capture and ChIP assays, Barnett
et al. established that a distal enhancer becomes bound by
ERa and recruits RNA-polymerase and co-activators to the
promoter of the CA12 gene.96 Small molecules targeting these
acidiﬁcation factors are currently under intensive research
(reviewed in Refs. 97 and 98)
Secondary Effects of NRs in the Warburg Effect
The “Warburg kinase” AKT and HIF1a
AKT is a potent oncogenic kinase, and controls the expres-
sion and localization of several glucose transporters and hex-
okinase activity (reviewed in Ref. 70). AKT is ampliﬁed in
breast and colon cancer99 and deregulation is common in
breast, prostate, pancreatic and gastric cancers.100–102 AKT
activation probably leads to HIF1a stabilization via
mTORC,103–106 even in the absence of hypoxia, further
enhancing the aerobic glycolysis phenotype. Furthermore
AKT deactivation of cell cycle checkpoints leads to rapid pro-
liferation, an increased demand for ATP, and thus depletion
of the cellular ATP/AMP ratio. This has the signiﬁcant effect
of deactivating AMPK, the “brake” that can limit the activity
of PI3K (the upstream effector of AKT and mTORC).107
Thus aberrant AKT imposes a positive feedback loop on cell
growth by inducing factors that elevate glucose and allow its
metabolism to generate ATP whilst repressing factors that
control normal cellular checkpoints. PTEN can negatively
regulate AKT signaling and is also frequently mutated in sev-
eral solid cancers.108–112
NR regulation of AKT and HIF1a
Crucially, AKT and HIF1a are activated and controlled in
multiple ways and the roles of several NRs in their regulation
are signiﬁcant. IGF1 which is stabilized by IGFBPs that in
turn are downstream of multiple NRs including VDR,113
ER114 and RXR115,116 can induce AKT activity along with
insulin itself. The PV mutation in the TRb causes hyper-
activation of AKT by excessive phosphorylation.117 T3 can
induce PI3K signaling via TR118–120 and TRIP230, a THR co-
factor, interacts with ARNT and HIF1a on the promoters of
hypoxia inducible genes.121 RARb is downregulated through
the PI3K/AKT pathway122 and all-trans retinoic acid can
activate the PI3K/AKT pathway via RARs in MEF’s and
COS-7 cells.123 FXR is also documented to enhance AKT sig-
naling,124,125 which can establish positive feedback as AKT
can activate PKC, which in turn phosphorylates FXR and
cause recruitment of PPARgC1.126 Interestingly, the co-
repressor NCOR1 binds to and represses key members of the
AKT/PI3K pathway and is repressed in thyroid cancers, pre-
sumably resulting increased AKT signaling.117
In addition to being regulated by NRs, activation of the
AKT pathway can lead to the deregulation of several NRs.
Perhaps surprisingly NUR77127 which is a potent inducer of
HIF1a128 is inactivated by AKT signaling, although this
may be cell type dependent.129 More predictably however
is the AKT mediated inhibition of RARa130 and RAR medi-
ated cell cycle arrest and differentiation. It is certainly possi-
ble therefore that AKT contributes to retinoid therapy
resistance.
Under normal conditions, metabolic requirement and
hypoxia are major factors governing the rate of metabolism
and therefore processes such as glycolytic ﬂux and synthesis
of fatty acids. NRs alter these cellular decisions by altering
their own transcription targets and inﬂuencing the activity of
several signaling pathways such as AKT/PI3K. If AKT can
cause the switch to aerobic glycolysis by stabilizing HIF-1,
then the switch is in part anticipatory of hypoxia rather than
reactive. Switching to the glycolytic pathway increases the
amount of lactic acid released by cells thereby causing an
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acidic environment around them. This selects for cells resist-
ant to an acidic environment in the rapidly dividing tumor,
prevents proper immune invasion and is damaging to sur-
rounding normal tissue, thereby giving further mechanisms
of selection for aggressive growth of the tumor.131
Impact on Cancer Diagnosis and Therapy
Highlighted in this review are nuclear receptors that impinge
on multiple aspects of the glycolytic pathway in cancer; some
support whilst other inhibit the Warburg effect, and their
activity is either enhanced or suppressed to allow the shift to
continue. Many NRs respond to dietary derived factors and
environmental cues and thus represent a large repertoire of
targets against which novel therapies can be directed, and
many of which have been attractive targets for differentiation
therapy. Stimulation of the NRs PPARd and the PPAR co-
factor PGC1a could have a signiﬁcant impact upon the ability
of cancer cells to generate lactate from pyruvate because of
their enhancement of the lactacte to pyruvate enzymatic
reaction.
Summary
NRs integrate endocrine signals and those from the microen-
vironment, to control cellular metabolism and growth. Sev-
eral NRs play key roles in the progression of tumours, either
through activation of their oncogenic properties, or through
silencing of their tumor suppressor ones. The current review
presents evidence that they are acutely involved in the shift
from oxidative phosphorylation to aerobic glycolysis, and
therefore play a central role in the Warburg effect. The War-
burg effect is now understood to be far more than the
enhancement of ATP generation, although this is still a major
component.
Given their central role in interpreting cellular signals,
and the wide-array of transcriptional targets they control,
NRs are well placed to allow the tumour to generate ATP
and the essential biomass precursors that result from divert-
ing glucose utilization to alternative pathways. Understanding
of how glucose transport mechanisms become enhanced in
cancer remains incomplete but is partially explained by a
combination of oncogene activation132 and tumour suppres-
sor gene inactivation.25 There is signiﬁcant evidence from the
studies outlined here that multiple NRs converge on several
high capacity/afﬁnity GLUT transporters to bring about gene
expression changes. Changes to NR co-factor expression,
ligand accessibility and the actual expression of NRs them-
selves are frequent events in many tumour types and lead to
a shift in the activity of their transcriptional targets. NRs
therefore provide multiple additional mechanisms through
which elevation of GLUT expression to pathological levels is
achieved by tumours. In parallel there is a growing apprecia-
tion of how NR transcriptomes can be modulated pharmaco-
logically and this therefore represents an exciting area of
research to target the distorted glucose metabolism that is
prevalent in malignancy.1,7,133–135
The integration between NRs, oncogenes, tumour suppres-
sor genes and cellular metabolism underlines the importance
of normal and distorted NR functions in tumour progression
and their continued suitability for clinical research and drug
development.
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